These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30468484)

  • 1. The correlation between the concentration of hepcidin in serum and the occurrence of insulin resistance and hyperandrogenemia in women with polycystic ovary syndrome.
    Pluta D; Franik G; Blukacz Ł; Kowalczyk K; Witkowska A; Wysocka M; Madej P
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7379-7384. PubMed ID: 30468484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased mean glucose levels in patients with polycystic ovary syndrome and hyperandrogenemia as determined by continuous glucose monitoring.
    Zhu JP; Teng YC; Zhou J; Lu W; Tao MF; Jia WP
    Acta Obstet Gynecol Scand; 2013 Feb; 92(2):165-71. PubMed ID: 23072215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of obesity on androstenedione to testosterone ratio in women with polycystic ovary syndrome (PCOS) and hyperandrogenemia.
    Misichronis G; Georgopoulos NA; Marioli DJ; Armeni AK; Katsikis I; Piouka AD; Saltamavros AD; Roupas ND; Panidis D
    Gynecol Endocrinol; 2012 Apr; 28(4):249-52. PubMed ID: 21970600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome.
    Panidis D; Tziomalos K; Macut D; Delkos D; Betsas G; Misichronis G; Katsikis I
    Fertil Steril; 2012 Feb; 97(2):494-500. PubMed ID: 22192350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients.
    Liao Y; Huang R; Sun Y; Yue J; Zheng J; Wang L; Tao T; Ma J; Li S; Liu W
    Reprod Biol Endocrinol; 2017 Jan; 15(1):9. PubMed ID: 28125989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of circulating hepcidin in association with iron excess, metabolic syndrome, and BMP-6 expression in granulosa cells in women with polycystic ovary syndrome.
    Kim JW; Kang KM; Yoon TK; Shim SH; Lee WS
    Fertil Steril; 2014 Aug; 102(2):548-554.e2. PubMed ID: 24875397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome.
    Sung YA; Oh JY; Chung H; Lee H
    Fertil Steril; 2014 Mar; 101(3):840-5. PubMed ID: 24424368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients.
    Karadağ C; Yoldemir T; Gogas Yavuz D
    Gynecol Endocrinol; 2017 Mar; 33(3):234-237. PubMed ID: 27908213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome.
    Alemzadeh R; Kichler J; Calhoun M
    Eur J Endocrinol; 2010 Jun; 162(6):1093-9. PubMed ID: 20371657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of decreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome.
    Luque-Ramírez M; Álvarez-Blasco F; Alpañés M; Escobar-Morreale HF
    J Clin Endocrinol Metab; 2011 Mar; 96(3):846-52. PubMed ID: 21209031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selected CNR1 polymorphisms and hyperandrogenemia as well as fat mass and fat distribution in women with polycystic ovary syndrome.
    Jędrzejuk D; Laczmański L; Kuliczkowska J; Lenarcik A; Trzmiel-Bira A; Hirnle L; Dorobisz U; Milewicz A; Lwow F; Urbanovych A; Słoka N
    Gynecol Endocrinol; 2015 Jan; 31(1):36-9. PubMed ID: 25093427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?
    Ozkaya E; Cakir E; Cinar M; Kara F; Baser E; Cakir C; Kucukozkan T
    Gynecol Endocrinol; 2012 Jun; 28(6):468-71. PubMed ID: 22103710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
    Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
    Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?
    Olszanecka-Glinianowicz M; Madej P; Zdun D; Bożentowicz-Wikarek M; Sikora J; Chudek J; Skałba P
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):55-61. PubMed ID: 22397743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No association of the G972S polymorphism of the insulin receptor substrate-1 gene with polycystic ovary syndrome in lean PCOS women with biochemical hyperandrogenemia.
    Marioli DJ; Koika V; Adonakis GL; Saltamavros AD; Karela A; Armeni AK; Tsapanos VS; Decavalas GO; Georgopoulos NA
    Arch Gynecol Obstet; 2010 Jun; 281(6):1045-9. PubMed ID: 20012307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alanine Aminotransferase Is a Marker of Lipotoxicity Consequences and Hyperandrogenemia in Women with Polycystic Ovary Syndrome.
    Belan M; Pelletier C; Baillargeon JP
    Metab Syndr Relat Disord; 2017 Apr; 15(3):145-152. PubMed ID: 28339345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of androgen levels on serum metabolic profiles in patients with polycystic ovary syndrome.
    Ting Z; Xinghua T; Xiao X; Lingchuan L; Xiaomei W; Tao Y
    Gynecol Endocrinol; 2024 Dec; 40(1):2352136. PubMed ID: 38733359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin resistance in polycystic ovary syndrome: hyperandrogenemia versus normoandrogenemia.
    Yildiz BO; Gedik O
    Eur J Obstet Gynecol Reprod Biol; 2001 Dec; 100(1):62-6. PubMed ID: 11728659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
    Yildiz BO; Yarali H; Oguz H; Bayraktar M
    J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.